Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on August 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Amylyx raising $500.2 million gross through 14.09 million shares at $35.50 each.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Amylyx raising $500.2 million gross through 14.09 million shares at $35.50 each
- Underwriters hold a 30-day option for 2.1135 million additional shares
- Net proceeds approximately $471.7 million, or $542.5 million if the option is fully exercised
- Funding targets potential U.S. avexitide launch, manufacturing capacity, research and development, and working capital
- Equity issuance creates dilution but materially strengthens resources ahead of potential commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.